Head-to-head · WeighScore
eMed vs Mevo Health
The verdict
Mevo Health takes it — 60.2/100 to 57.4/100.
Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | eMed | Mevo Health |
|---|---|---|
| WeighScore | 57.4/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #398 | #326 |
| Semaglutide | Not disclosed | $199/mo (all doses, compounded) |
| Tirzepatide | Not disclosed | $259/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #398 · C
Strengths
- Prescribes FDA-approved branded GLP-1s (semaglutide and tirzepatide)
- At-home blood collection makes lab work convenient
- Clinician review and ongoing side-effect plus adherence support
- Works with CVS Caremark so eligible employees can buy through benefits
- Established digital health company with national scale
Where it loses points
- Distributed mainly via employers, with limited direct cash-pay access
- No public transparent monthly price for individuals
- Eligibility and subsidy depend on what the employer chooses to cover
- Best suited to workforces, not casual self-pay shoppers
Graded #326 · C
Strengths
- LegitScript verification badge on multiple pages
- Publishes the FDA compounded-medication disclaimer
- Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
- Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
- Public entry-level pricing surfaced
Where it loses points
- States served not listed on any public page
- Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
- No formal Medical Director role disclosed
- Only 'as low as' entry pricing shown — no per-dose itemization
- No SOC 2 certification claimed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.